Sagimet Biosciences Inc. Stock Price, News & Analysis

Ascletis (HKEX:1672) completed a pre-NDA consultation with China NMPA for denifanstat (ASC40) for moderate-to-severe acne vulgaris, initiated in June 2025 and completed in October 2025, and plans to submit an NDA soon.

Ascletis completed Phase II (NCT05104125) and Phase III (NCT06192264) studies; the Phase III met all primary, key secondary and secondary efficacy endpoints (ITT) and showed statistically significant improvement versus placebo. Denifanstat demonstrated a favorable safety and tolerability profile: all related TEAEs were Grade 1–2, with no related Grade 3–4 TEAEs, SAEs, permanent discontinuations, or withdrawals. Phase III results were presented at EADV Congress on Sept 17, 2025. Ascletis holds exclusive Greater China rights via license from Sagimet (Nasdaq: SGMT).

Sagimet Biosciences (Nasdaq: SGMT) will present Phase 2b FASCINATE-2 secondary analyses showing that denifanstat produced a ≥2-stage fibrosis improvement in F3 MASH patients and improved fibrosis and biomarkers in qFibrosis stage 4 MASH patients.

The data, described as showing a robust anti-fibrotic effect by conventional and AI-based digital pathology and improved non-invasive test biomarkers in a qF4 subpopulation, was selected as a Poster of Distinction for AASLD—The Liver Meeting 2025 on November 10, 2025 in Washington, DC; presenting author is Rohit Loomba, M.D., M.H.Sc.

Sagimet Biosciences (Nasdaq: SGMT) has initiated dosing in a Phase 1 pharmacokinetic (PK) trial combining their oral FASN inhibitor denifanstat with THR-β agonist resmetirom. The trial will enroll approximately 40 healthy adult participants across 2 cohorts to evaluate drug interactions, safety, and tolerability.

The study aims to inform optimal dosing for a future Phase 2 combination trial in F4 MASH (metabolic dysfunction-associated steatohepatitis) patients. Topline data is expected in H1 2026. The combination therapy builds on promising preclinical data presented at EASL 2024, which demonstrated synergistic effects on liver disease markers when combining a FASN inhibitor with resmetirom.

Sagimet Biosciences (Nasdaq: SGMT), a clinical-stage biopharmaceutical company, will participate in a panel discussion at Fierce Biotech Week in Boston, MA from October 7-9, 2025. The company's Senior Vice President of Research and Development, Dr. Marie O'Farrell, will join a panel focused on AI/Machine Learning applications in biotechnology.

The presentation, scheduled for October 9, 2025, at 11:15 AM ET, will highlight Sagimet's use of AI-based digital pathology platforms in clinical trials, particularly for analyzing liver biopsies in metabolic dysfunction associated steatohepatitis (MASH) drug development.

Ascletis presented successful Phase III clinical trial results for denifanstat (ASC40), a first-in-class FASN inhibitor for acne treatment, at EADV Congress 2025. The trial, involving 480 patients with moderate to severe acne vulgaris, demonstrated that denifanstat met all primary, key secondary, and secondary efficacy endpoints.

Key achievements include 33.17% treatment success versus 14.58% for placebo, 57.38% reduction in total lesion count, and 63.45% reduction in inflammatory lesions. The drug showed a favorable safety profile, with TEAEs comparable to placebo (58.6% vs 56.3%). Ascletis plans to submit an NDA to China's NMPA following encouraging pre-NDA consultation feedback.

Sagimet Biosciences (Nasdaq: SGMT) announced positive Phase 3 trial results for denifanstat in treating moderate to severe acne, to be presented at the EADV Congress 2025. The trial, conducted by partner Ascletis in China, met all primary and secondary endpoints with 480 patients receiving either denifanstat 50mg or placebo daily for 12 weeks.

Key results include an 18.6% placebo-adjusted increase in treatment success rate, 22.0% reduction in total lesions, and 20.2% reduction in inflammatory lesions. Additionally, Sagimet has initiated a Phase 1 trial for TVB-3567, a second FASN inhibitor, for acne treatment.

Sagimet Biosciences (Nasdaq: SGMT) announced its participation in the 9th Annual MASH Drug Development Summit from September 29-October 1, 2025, in Boston. The company will deliver two oral presentations and participate in a panel discussion focused on their FASN inhibitor denifanstat.

Dr. Marie O'Farrell will present findings on denifanstat's mechanism of action in MASH, including combination treatments with semaglutide and resmetirom, highlighting results from the Phase 2b FASCINATE-2 study. Dr. Wen-Wei Tsai will discuss the application of AI-based digital pathology in evaluating denifanstat's anti-fibrotic effects in MASH patients with F3 fibrosis.

Sagimet Biosciences (Nasdaq: SGMT), a clinical-stage biopharmaceutical company focused on developing therapeutics for metabolic and fibrotic pathways, has announced its participation in two upcoming investor conferences in September 2025.

The company will present at the Cantor Global Healthcare Conference on September 3, featuring a fireside chat at 1:35 p.m. ET, and the H.C. Wainwright 27th Annual Global Investment Conference on September 9. A webcast of the Cantor presentation will be available on Sagimet's website for 90 days after the event.

Sagimet Biosciences (NASDAQ:SGMT) reported significant progress in Q2 2025, highlighted by positive Phase 3 trial results for denifanstat in acne treatment through its partner Ascletis in China. The trial met all primary endpoints, showing 33.2% treatment success vs. 14.6% for placebo.

The company initiated a Phase 1 trial for TVB-3567, another FASN inhibitor for acne treatment in the U.S. Additionally, Sagimet plans to start a Phase 1 trial evaluating denifanstat combined with resmetirom for MASH treatment in 2H 2025. As of June 30, 2025, the company reported $135.5 million in cash and equivalents, with a net loss of $10.4 million for Q2 2025.